LEADER 04581nam 22013573a 450 001 9910367759003321 005 20250203235431.0 010 $a9783039213146 010 $a3039213148 024 8 $a10.3390/books978-3-03921-314-6 035 $a(CKB)4100000010106127 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/60492 035 $a(ScCtBLL)7e0c7713-9faa-412b-9229-7d8e96d8968f 035 $a(OCoLC)1163814219 035 $a(oapen)doab60492 035 $a(EXLCZ)994100000010106127 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aTargets, Tracers and Translation - Novel Radiopharmaceuticals Boost Nuclear Medicine$fGerald Reischl 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (214 p.) 311 08$a9783039213139 311 08$a303921313X 330 $aThis is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences. 606 $aMedicine$2bicssc 610 $apretargeting 610 $aradioiodination 610 $aneurodegeneration 610 $aphosphoramidon 610 $aGRPR 610 $amolecular imaging 610 $aallosteric modulator 610 $aradiosynthesis 610 $aseparation 610 $a?-CIT. 610 $aPET/CT imaging 610 $atechnetium-99m 610 $agastrin-releasing peptide receptor 610 $ametabotropic glutamate receptor subtype 5 610 $aglutamate 610 $aoncogenic fusions 610 $aFusarinine C 610 $ahypoxia 610 $atirapazamine (TPZ) 610 $a68Ga 610 $asentinel lymph node 610 $a99mTc-radioligand 610 $aiodine-131 610 $aelectrophilic radioiodination 610 $a4-dioxide (BTDO) 610 $aminigastrin 610 $aceftriaxone 610 $atropomyosin receptor kinase 610 $acarbonic anhydrase IX 610 $aABP688 610 $aNPY(Y1)R 610 $aMMPEP 610 $aradiosensitizer 610 $aneprilysin-inhibition 610 $aradiochemistry 610 $agirentuximab 610 $abenzotriazine-1 610 $agallium-68 610 $acholecystokinin-2 receptor 610 $atumor targeting 610 $aradioimmunotherapy 610 $asalivary gland uptake 610 $ametabolic stability 610 $atumor hypoxia 610 $amultimerization 610 $aoxidizing agent 610 $aneuroinflammation 610 $agastrin-releasing peptide 610 $adextran 610 $acarbon-11 610 $apeptide heterodimers 610 $aapparent molar activity 610 $aradiometals 610 $amicroglia 610 $arituximab 610 $a[18F]FMISO 610 $a[11C]meta-hydroxyephedrine 610 $aIodo-GenŽ 610 $amannose 610 $a177Lu-radiopharmaceuticals 610 $aazomycin nucleosides 610 $abreast cancer 610 $aclick chemistry 610 $asmall animal imaging 610 $aSR 4317 610 $abenzotriazine-1-monoxide (BTMO) 610 $abombesin 610 $aprostate cancer 610 $aChloramine T 610 $a99mTc-radiopharmaceuticals 610 $aketamine 610 $aPSMA-617 610 $apositron emission tomography 610 $ahydrazinonicotinic acid (HYNIC) 610 $arenal cell carcinomas 610 $a[18F]PSS232 610 $aPET 610 $aendoradiotherapy 615 7$aMedicine 700 $aReischl$b Gerald$01329324 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910367759003321 996 $aTargets, Tracers and Translation ? Novel Radiopharmaceuticals Boost Nuclear Medicine$93039429 997 $aUNINA